Endocrinologic side effects of oncologic treatment with anti-CTLA-4-antibodies;Endokrinologische Nebenwirkungen einer onkologischen Therapie mit Anti-CTLA-4-Antikörpern

Deutsche Medizinische Wochenschrift

Volumn 139, Issue 19, 2014, Pages 966-1000

  Fischli, S ^a   Allelein, S ^a   Zander, T ^b   Henzen, C ^a  

^a Luzerner Kantonsspital   (Switzerland)

^b Luzerner Kantonsspital   (Switzerland)

Author keywords

adrenalitis; anti CTLA 4 Antibodies; hypophysitis; immune related adverse events; Ipilimumab; thyroiditis

Indexed keywords

ANTI CTLA 4 ANTIBODY; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; MONOCLONAL ANTIBODY;

ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; ENDOCRINE DISEASE; HORMONAL THERAPY; HUMAN; IMMUNOPATHOLOGY; IMMUNOTHERAPY; ADRENAL DISEASE; BRAIN TUMOR; CHEMICALLY INDUCED DISORDER; COLITIS; DRUG ANTAGONISM; FOLLOW UP; HYPERTHYROIDISM; HYPOPITUITARISM; IMMUNOLOGY; LIVER TUMOR; LUNG TUMOR; MALE; MELANOMA; METASTASIS; MIDDLE AGED; SKIN TUMOR; THYROIDITIS;

ADRENAL GLAND DISEASES; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; COLITIS; CTLA-4 ANTIGEN; FOLLOW-UP STUDIES; HUMANS; HYPERTHYROIDISM; HYPOPITUITARISM; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; THYROIDITIS;

EID: 84899652192     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0034-1369961     Document Type: Article

References (25)

1. Ascierto P. A., Simeone E., Sznol M. et al. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol: 2010; 37 508 516
2. Blansfield J. A., Beck K. E., Tran K. et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother: 2005; 28 593 598 (Pubitemid 41533093)
3. Carmichael J. D. Update on the diagnosis and management of hypophysitis. Curr Opin Endocrinol Diabetes Obes: 2012; 19 314 321
4. Carpenter K. J., Murtagh R. D., Lilienfeld H. et al. Ipilimumab-induced hypophysitis: MR imaging findings. Am J Neuroradiol: 2009; 30 1751 1753
5. Caturegli P., Newschaffer C., Olivi A. et al. Autoimmune hypophysitis. Endocr Rev: 2005; 26 599 614 (Pubitemid 41127273)
6. Corsello S. M., Barnabei A., Marchetti P. et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab: 2013; 98 1361 1375
7. Corsello S. M., Salvatori R., Barnabei A. et al. Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not). Cancer Chemother Pharmacol: 2013; 72 489 490
8. Coursin D. B., Wood K. E. Corticosteroid supplementation for adrenal insufficiency. JAMA: 2002; 287 236 240 (Pubitemid 34251950)
9. Di Giacomo A. M., Biagioli M., Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol: 2010; 37 499 507
10. Dillard T., Yedinak C. G., Alumkal J. et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary: 2010; 13 29 38
11. Dillman R. O. Cancer immunotherapy. Cancer Biother Radiopharm: 2011; 26 1 64
12. Fassett D. R., Couldwell W. T. Metastases to the pituitary gland. Neurosurg Focus: 2004; 16 E8
13. Hodi F. S., O'Day S. J., McDermott D. F. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med: 2010; 363 711 723
14. Juszczak A., Gupta A., Karavitaki N. et al. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol: 2012; 167 1 5
15. Min L., Vaidya A., Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol: 2011; 164 303 307
16. Min L., Vaidya A., Becker C. Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency. Endocr Pract: 2012; 18 351 355
17. Molitch M. E., Gillam M. P. Lymphocytic hypophysitis. Horm Res: 2007; 68 05 145 150
18. Peggs K. S., Quezada S. A., Allison J. P. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev: 2008; 224 141 165
19. Persani L. Clinical review: Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J Clin Endocrinol Metab: 2012; 97 3068 3078
20. Rivera J. A. Lymphocytic hypophysitis: disease spectrum and approach to diagnosis and therapy. Pituitary: 2006; 9 35 45
21. Torino F., Barnabei A., De Vecchis L. et al. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist: 2012; 17 525 535
22. Torino F., Barnabei A., Paragliola R. M. et al. Thyroid as unintended side effect of anticancer drugs. Thyroid: 2013
23. van der Hiel B., Blank C. U., Haanen J. B. et al. Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab. Clin Nucl Med: 2013; 38 e182 e184
24. Warner M. H., Beckett G. J. Mechanisms behind the non-thyroidal illness syndrome: an update. J Endocrinol: 2010; 205 1 13
25. Weber J. S., Kahler K. C., Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol: 2012; 30 2691 2697